Sutro Biopharma, Inc.
STRO
$20.48
-$0.83-3.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -56.25% | 49.94% | 65.18% | -34.36% | -38.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -56.25% | 49.94% | 65.18% | -34.36% | -38.31% |
| Cost of Revenue | -35.11% | -38.66% | -33.97% | -14.46% | 2.17% |
| Gross Profit | 16.49% | 71.29% | 66.35% | -28.92% | -142.16% |
| SG&A Expenses | -30.14% | -27.91% | -15.34% | -26.39% | -17.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.25% | -36.87% | -30.97% | -16.77% | -1.98% |
| Operating Income | 20.36% | 62.02% | 55.99% | -5.01% | -56.00% |
| Income Before Tax | 12.42% | 36.70% | 15.07% | -98.29% | -93.22% |
| Income Tax Expenses | -104.10% | -104.85% | -103.94% | -85.18% | -86.72% |
| Earnings from Continuing Operations | 13.45% | 37.36% | 15.99% | -74.88% | -67.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.45% | 37.36% | 15.99% | -74.88% | -67.70% |
| EBIT | 20.36% | 62.02% | 55.99% | -5.01% | -56.00% |
| EBITDA | 20.44% | 63.78% | 57.78% | -4.90% | -59.51% |
| EPS Basic | 30.54% | 44.58% | 24.76% | -58.23% | -35.36% |
| Normalized Basic EPS | 31.39% | 58.37% | 51.94% | -3.08% | -26.15% |
| EPS Diluted | 30.54% | 44.58% | 24.76% | -58.23% | -35.36% |
| Normalized Diluted EPS | 31.39% | 58.37% | 51.94% | -3.08% | -26.15% |
| Average Basic Shares Outstanding | 39.73% | 17.06% | 10.21% | 18.41% | 26.95% |
| Average Diluted Shares Outstanding | 39.73% | 17.06% | 10.21% | 18.41% | 26.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |